Results 81 to 90 of about 100,658 (276)

Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea

Clinical Kidney Journal, 2017
Thrombotic microangiopathy (TMA), characterized by organ injury occurring consequent to severe endothelial damage, can manifest in a diverse range of diseases.
V. Brocklebank, D. Kavanagh
semanticscholar   +1 more source

The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation

Transplant Infectious Disease, EarlyView.
ABSTRACT Introduction Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept‐use to no belatacept‐use in KT recipients.
Hareesh Singam, Abdinoor Abdi, Wyatt Tarter, Ben Langworthy, Adam Bregman, Karam M. Obeid   +5 more
wiley   +1 more source

Diagnosis and Treatment of Thrombotic Thrombocytopenic Purpura Developed During Gestation: Literature Review and Case Report

Клиническая онкогематология, 2014
This paper presents a literature review on state of art in issues of etiology, pathogenesis, clinical features and diagnosis of thrombotic thrombocytopenic purpura (ТТP or Moschcowitz’s disease).
V. V. Voitsekhovskii, L. B. Filatov, A. V. Pivnik, P. V. Avdonin, T. V. Esenina, A. G. Sudakov   +5 more
doaj   +1 more source

Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune‐mediated thrombotic thrombocytopenic purpura in the United States

Research and Practice in Thrombosis and Haemostasis, 2022
Background Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is a life‐threatening thrombotic microangiopathy. Due to its rarity, epidemiology and real‐world outcomes data are scarce.
Ayoade Adeyemi, Francesca Razakariasa, Alexandra Chiorean, Rui dePassos Sousa   +3 more
doaj   +1 more source

A Rare Case of Gemcitabine-Induced Thrombotic Microangiopathy (TMA) in the Treatment ofMetastatic Nasopharyngeal Carcinoma, presenting to Nephrology Division Khyber TeachingHospital, Peshawar [PDF]

, 2023

openalex   +1 more source

Adverse Renal Outcomes in Patients With Mesothelioma—A Territory‐Wide Real‐World Data

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Advances in mesothelioma management have translated into longer patient survival and different treatment‐related side effects including nephrotoxicity. The risk of developing adverse renal outcomes in patients with mesothelioma and associated risk factors remains undefined.
Wang Chun Kwok, James Chung Man Ho, Isaac Sze Him Leung, Desmond Yat Hin Yap   +3 more
wiley   +1 more source

Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies

Kidney International Reports
Thrombotic microangiopathy (TMA) represents a heterogeneous group of disorders characterized by microvascular thrombosis and end-organ damage. Pregnancy-associated thrombotic microangiopathy (p-TMA) has emerged as a distinct clinical entity with unique ...
Manuel Urra, Shannon Lyons, Corina Gabriela Teodosiu, Richard Burwick, Anuja Java   +4 more
doaj   +1 more source

The Complement System in Post‐Transplant Kidney Injury

Organ Medicine, EarlyView.
Mengsi Hu
wiley   +1 more source

Miliary Tuberculosis With Immune Thrombocytopenia in 50‐Year‐Old Ethiopian Woman: A Case Report and Brief Review of Literature

Clinical Case Reports, Volume 14, Issue 2, February 2026.
Diffuse petechiae and non‐palpable purpura (lower extremities below knee, admission photo). ABSTRACT Immune thrombocytopenia (ITP) is a rare but recognized hematologic complication of tuberculosis (TB), particularly miliary TB. We present a case of a 50‐year‐old female with severe thrombocytopenia and hemorrhagic manifestations secondary to miliary TB.
Hayatu Awel Abdela, Tamirat Godebo Woyimo, Ragasa Getachew Bayisa, Sisay Tagese Tafese   +3 more
wiley   +1 more source

PROTEOLYTIC PROCESSING OF VON WILLEBRAND FACTOR BY ADAMTS13 AND LEUKOCYTE PROTEASES-rev1-MJHID-2013

Mediterranean Journal of Hematology and Infectious Diseases, 2014
ADAMTS13 is a 190 kDa zinc protease encoded by a gene located on chromosome 9q34.   This protease specifically hydrolyzes von Willebrand factor (VWF) multimers, thus causing VWF size reduction.
Raimondo De Cristofaro
doaj